CSLLY News and Press, CSL Ltd ADR From 02/15/23

Summary Haemonetics surpassed sell-side expectations with healthy revenue growth from Plasma and Hospital, but margin leverage was lacking due to the ongoing impact of inflation and supply chain issues. The company extended its non-exclusive supply agreement with CSL for another two yea...

Summary CSL Limited's 1H FY 2023 net profit came in +10% above analysts' expectations, as a result of both solid revenue growth and significant margin improvement. I also have a positive opinion about the planned introduction of the new hemophilia B gene therapy product in the US, and t...

CSL Limited (CSLLY) Q2 2023 Earnings Conference Call Feb 13, 2023, 07:00 PM ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton - Chief Financial Officer Paul McKenzie - Chief Operating Officer C...

Summary The Project $1M portfolio had its worst year in 2022, down 35%, and now marginally behind the S&P500, over the 7-year period since inception. Visa and Mastercard had a relatively good performance, which wasn't enough to make up for very poor performance everywhere else. ...

Summary ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humoral immunodeficiency. Shares have extended the rally in 2023 and further up...

Summary The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights. This article will discuss the 10 largest biotech companies (by ma...

Summary VPL's portfolio is highly diversified, invests significantly in sectors with high growth potential, has a low expense ratio, and is trading at a marginal discount. Though VPL's current yield is not excessively high, it seems to be sustainable and the fund generates a high enough...

CSL ( OTCPK:CSLLY ) said Monday it appointed its COO Paul McKenzie as CEO and managing director, effective March 6. McKenzie will succeed Paul Perreault, who will remain as a strategic adviser to assist in an orderly transition till he retires on September 6. Prior to joining...

CSL Announces Next CEO & Managing Director CSL Announces Next CEO & Managing Director Canada NewsWire Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from 6 March 2023 MELBOURNE, Australia , Dec. 12, 2022 ...

CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics PR Newswire CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and othe...